Menin inhibitors in the treatment of acute myeloid leukemia
Top Cited Papers
Open Access
- 6 February 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 145 (6) , 561-566
Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatment, AML remains challenging to cure, particularly in patients with specific genetic abnormalities. Menin inhibitors have emerged as a promising therapeutic approach, targeting key genetic drivers of AML, such as KMT2A (lysine methyl transferase 2A) rearrangements and NPM1 mutations. Here, we review the clinical value of menin inhibitors, highlighting their mechanism of action, efficacy, safety, and potential to transform AML treatment.Keywords
This publication has 47 references indexed in Scilit:
- 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialThe Lancet Haematology, 2023
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged LeukemiaCancer Cell, 2019
- Mutant NPM1 Maintains the Leukemic State through HOX ExpressionCancer Cell, 2018
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In VivoCancer Cell, 2015
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Menin Critically Links MLL Proteins with LEDGF on Cancer-Associated Target GenesCancer Cell, 2008
- The Epigenomics of CancerCell, 2007
- The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated LeukemogenesisCell, 2005
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001